Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.
about
Recent developments in adenosine receptor ligands and their potential as novel drugsThe Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine DerivativesAdenosine and osteopontin contribute to the development of chronic obstructive pulmonary disease.Adenosine signaling during acute and chronic disease statesXanthines as adenosine receptor antagonists.Structure based prediction of subtype-selectivity for adenosine receptor antagonistsBig opportunities for small molecules in immuno-oncology.The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Role of adenosine A(2B) receptors in inflammation.Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumorsAdenosine signaling and the regulation of chronic lung disease.Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease.Targeting A2 adenosine receptors in cancer.Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3-d]pyrimidine derivatives.Characterisation of endogenous A2A and A2B receptor-mediated cyclic AMP responses in HEK 293 cells using the GloSensor™ biosensor: Evidence for an allosteric mechanism of action for the A2B-selective antagonist PSB 603.
P2860
Q27687253-2E220748-357E-4D6D-8EB9-F7EDE6CB7D88Q28551225-32345783-7784-4363-AA55-989E6FD979EFQ33552900-0BB808DE-2116-479C-A47E-1CA72B1754FFQ34035228-0D3681A2-B199-4426-83F0-7AAB8945EF56Q34139398-AD803CBB-B594-4625-AA0F-6033658FAF0DQ34306247-DFBD1E9E-2D91-4098-A708-F4986F647B6EQ34487689-858D4C80-0BD2-469F-962F-3A809ABA6299Q36832901-A26976D0-6B02-4C4B-98D2-987B7B3C73D0Q37079141-66E314B5-AF90-4B58-8BBA-2F1EE7222DA5Q37108355-51F82C37-9702-4F00-ADAE-FBBB92402724Q37157425-936C92BB-4D5C-4AFF-8B69-F8DDC5C5AC6EQ37345181-5E42C619-25A6-4BEE-8EBC-5AB5A1292475Q37599075-2AEA8312-0F70-4ED2-A5BC-1EA4181A522EQ39125149-E2B76AD0-2904-46AF-BAB1-4101F206DF0BQ39775269-8AA87239-0302-448F-92EB-63347EE6741EQ47384028-AAF0138A-40D9-4B44-AB6D-16A96031EAE7Q47437537-324B4049-80F7-4278-BC0D-B655057ACC31
P2860
Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Progress in the discovery of s ...... onists as clinical candidates.
@en
Progress in the discovery of s ...... onists as clinical candidates.
@nl
type
label
Progress in the discovery of s ...... onists as clinical candidates.
@en
Progress in the discovery of s ...... onists as clinical candidates.
@nl
prefLabel
Progress in the discovery of s ...... onists as clinical candidates.
@en
Progress in the discovery of s ...... onists as clinical candidates.
@nl
P2860
P1476
Progress in the discovery of s ...... onists as clinical candidates.
@en
P2093
Jeff Zablocki
Rao V Kalla
P2860
P2888
P356
10.1007/S11302-008-9119-X
P577
2008-06-21T00:00:00Z